#Dubai #UAE #Co-Diagnostics #PCR platform #CoMira Diagnostics

Co-Diagnostics Showcases PCR Innovations at World Health Expo Labs in Dubai

Co-Diagnostics, Inc. (OTC: CODX), recognized for its cutting-edge molecular diagnostics technology, is gearing up to participate in the World Health Expo Labs Dubai, set for February 10-13, 2026. This international exhibition, held at the Dubai World Trade Centre, represents a convergence of professionals from the healthcare sector, including laboratory leaders, diagnostics innovators, and technology service providers, with the common goal of advancing medical laboratory science.

The World Health Expo, previously known as Medlab Middle East, is renowned for addressing the latest challenges and developments in the field. Co-Diagnostics will be at Booth #S17.C79, an opportunity for the company to display its innovative products, particularly its Co-Dx PCR platform, which is currently undergoing clinical studies in the United States.

This significant showcase comes on the heels of Co-Diagnostics' recently formed joint venture with Arabian Eagle Manufacturing, called CoMira Diagnostics. Located in Saudi Arabia, CoMira is set to localize the manufacturing and distribution of Co-Diagnostics’ advanced technologies across Saudi Arabia and 18 other nations in the Middle East and North Africa (MENA) region. This partnership underscores Co-Diagnostics' commitment to expanding access to high-quality diagnostic solutions in these emerging markets.

The World Health Expo serves as a pivotal platform for Co-Diagnostics to engage with key regional players, highlighting its mission to enhance the availability of molecular diagnostics for better healthcare outcomes. The company anticipates building relationships that will support its broader strategy in the region, aiming for increased awareness and understanding of its molecular diagnostic tests, which are pivotal in identifying and managing diseases.

Co-Diagnostics' Co-Dx PCR platform, which includes the Co-Dx Home™, Co-Dx Pro™, and a dedicated mobile application, is an integral part of the company's offerings. However, it's important to note that all associated tests and applications of this technology are still under review by the FDA and other regulatory bodies and are not yet available for commercial sale. The platform is designed not only for infectious disease detection but also aims to cater to genetic testing needs, marking a significant evolution in the molecular diagnostics arena.

The inclusion of Co-Diagnostics in this prestigious event aligns with its goal of leveraging international partnerships and growth in the diagnostics sector. Furthermore, the company actively emphasizes the importance of innovation and collaboration in the evolving landscape of healthcare technology.

Visitors interested in the latest advancements in molecular diagnostics are encouraged to stop by the Co-Diagnostics and CoMira representatives at the World Trade Center Utah booth. This collaboration with the World Trade Center Utah is aimed at facilitating international collaborations and market expansion for Utah-based companies, which enhances Co-Diagnostics' potential for growth and impact.

In conclusion, Co-Diagnostics is set to make a significant mark at the World Health Expo Labs in Dubai by exhibiting its cutting-edge PCR technologies and highlighting its strategic initiatives in the MENA region. This participation not only reinforces its commitment to innovative healthcare solutions but also fosters vital connections that could lead to significant advancements in the diagnostic landscape.